Drug Trial Radar · NCT07092007
NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Newish Technology (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 related Cervical, vaginal, and vulvar intraepithelial neoplasia (LSIL and HSIL) patients (cohort A) and HPV-16 related cervical cancer patients (cohort B).
Conditions
- Intraepithelial Neoplasia
- Cervical Cancer
Interventions
NWRD09 administered by intramuscular injectionBiological
NWRD09 administered by intramuscular injection according to the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety(Cohort A and B)Time frame: From first administration of NWRD09 to 14 days after the last administration
- Dose-limiting toxicity (DLT) (Cohort A and B)Time frame: 14 days after the first administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Heze Municipal Hospita
Heze, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.